trending Market Intelligence /marketintelligence/en/news-insights/trending/IlEZWtpL3cqv-472wg76fA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Memphasys closes sale of gels business to Dycent Biotech

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Memphasys closes sale of gels business to Dycent Biotech

Memphasys Ltd. completed the sale of its gels business to Dycent Biotech (Shanghai) Co. Ltd.

The $130,000 deal includes Memphasys U.S. unit NuSep Inc., a manufacturing plant and related patents. The transaction was announced April 2016, when Memphasys was still known as NuSep Holdings Ltd.

The deal closed after Memphasys fulfilled the contractual requirement of commissioning of the gels manufacturing plant, which was relocated to Shanghai.